Last reviewed · How we verify
Placebo of Oseltamivir
Placebo of Oseltamivir is a Small molecule drug developed by Chinese University of Hong Kong. It is currently FDA-approved for Control arm in oseltamivir clinical trials. Also known as: Tamiflu Placebo.
A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect.
A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect. Used for Control arm in oseltamivir clinical trials.
At a glance
| Generic name | Placebo of Oseltamivir |
|---|---|
| Also known as | Tamiflu Placebo |
| Sponsor | Chinese University of Hong Kong |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Placebos are inert substances used as controls in clinical trials to establish the true efficacy of an active drug by comparison. Any observed effects in placebo groups are attributed to the placebo effect (psychological and contextual factors) rather than direct pharmacological action. In this case, it is a placebo formulation matching the appearance of oseltamivir (an antiviral) but containing no active drug.
Approved indications
- Control arm in oseltamivir clinical trials
Common side effects
Key clinical trials
- Phase III Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy of JKN2301 Dry Suspension in Pediatric Patients Aged 2 to Under 12 Years With Influenza (PHASE3)
- Study to Assess the Safety and Efficacy of ZX-7101A for Oral Suspension in Chinese Pediatric Participants 2 to 11 Years of Age With Influenza (PHASE3)
- Safety and Efficacy of ADC189 in Children 2-11 Years Old With Influenza (PHASE3)
- Study to Assess the Safety and Efficacy of ZX-7101A in Children Aged 5-11 Years With Influenza (PHASE3)
- Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated With Experimental Influenza Virus (MK-4482-019) (PHASE1)
- Severe Influenza Trial of ARbidol (PHASE3)
- Baloxavir in Combination With Oseltamivir in Allogenic Bone Marrow Transplant Recipients With Influenza (PHASE2, PHASE3)
- Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo of Oseltamivir CI brief — competitive landscape report
- Placebo of Oseltamivir updates RSS · CI watch RSS
- Chinese University of Hong Kong portfolio CI
Frequently asked questions about Placebo of Oseltamivir
What is Placebo of Oseltamivir?
How does Placebo of Oseltamivir work?
What is Placebo of Oseltamivir used for?
Who makes Placebo of Oseltamivir?
Is Placebo of Oseltamivir also known as anything else?
What development phase is Placebo of Oseltamivir in?
Related
- Manufacturer: Chinese University of Hong Kong — full pipeline
- Indication: Drugs for Control arm in oseltamivir clinical trials
- Also known as: Tamiflu Placebo
- Compare: Placebo of Oseltamivir vs similar drugs
- Pricing: Placebo of Oseltamivir cost, discount & access